YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Vinorelbine
Related studies linked through entity extraction aliases.
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
- Status
- RECRUITING
- Phase
- PHASE3
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
- Status
- RECRUITING
- Phase
- PHASE3
Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
- Status
- RECRUITING
- Phase
- NA
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3